Breast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
|
|
- Amberly Lambert
- 5 years ago
- Views:
Transcription
1 Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime
2 Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy Bone Loss Pfeilschifter J and Diel IJ. J Clin Oncol 2000;18:
3 Incidence of Cancer Treatment Induced Ovarian Failure Ovarian failure after adjuvant chemotherapy Earlier menopause by an average of 5 to 10 years CMF 63% - 85% of patients FAC 50% overall Age yr 33% yr 96% 50 yr 100% Samaan NA. Cancer. 1978;41:2084. Tormey DC. NCI Monographs. 1986;1:75. Jordan VC. Cancer Res. 1987;47:624. Bruning P, et al. Br J Cancer. 1990;61:308.
4 Effect of Premature Menopause in Breast Cancer Patients
5 Chemotherapy-Induced Menopause Results in Rapid Bone Loss N= 49 * * Total spine * Femoral neck * *P= vs baseline. Shapiro CL et al. J Clin Oncol. 2001;19:
6 Bone Turnover Increases After Chemotherapy-Induced Menopause 59 * Osteocalcin Bone alkaline phosphatase (ALP) *P=0.01 vs baseline; P= vs baseline; P=0.05 vs baseline. Shapiro CL et al. J Clin Oncol. 2001;19:
7 Age Annual Incidence of Vertebral Fractures in Breast Cancer patients Patients followed for 3 years with X-rays every 6 months Controls (%) N=776 Breast Cancer at diagnosis (%) N=352 Breast Cancer at Soft- Tissue relapse (%) N=82 < All (*4.7) 19.21(*22.7) * age-adjusted risk of vert fx (Odds ratio) Kanis J. Br J Cancer. 1999;79:1179.
8 Cumulative fracture (%) Cumulative fracture (%) Osteoporotic Fracture Risk Is Increased in Breast Cancer Survivors Results from the Women s Health Initiative Control 80,848 Breast cancer survivors 5, * Hip Clinical spine Lower arm/wrist Other Total Results from Cox regression models indicated that breast ca survivors had a 28% increased risk 6 *P=0.049; P=0.001; P< Chen Z et al. J Bone Miner Res. 2003;18(suppl 2):S22. Abstract 1077.
9 Effect of Hormonal Therapy on Bone Mass
10 Premenopausal Effect of Tamoxifen on BMD Lumbar BMD (% change from baseline)/ year Tamoxifen Postmenopausal Powles et al JCO14: 78-84, Tamoxifen
11 Aromatase Inhibitors Cholesterol Pregnenolone Progesterone Aldosterone Androstenedione A Estrone Estradiol X Testosterone X A Cortisol
12 Prevention and Management of Osteoporosis in Breast Cancer Patients Estrogen therapy is contraindicated Raloxifene therapy would likely be effective but few data regarding its long-term role;not approved either for prevention or treatment of breast cancer Tamoxifen prevents bone loss in post-menopausal women, but is quickly being replaced by aromatase inhibitors Forteo (PTH 1-34) is contraindicated in women who have received breast radiation Safety in those at risk for breast cancer recurrence has not been studied Bisphosphosphonates remain the mainstay of therapy 0.5-1% of patients treated with high dose (monthly) intravenous bisphosphonates will develop osteonecrosis, most commonly of the jaw or maxilla
13 Chemotherapy-Induced Premature Menopause - Risedronate BMD (% change) Lumbar Spine years Placebo Risedronate Study period BMD (% change) Femoral Neck years Placebo Risedronate Study period Adapted with permission from Delmas PD et al. J Clin Oncol. 1997;15:
14 BMD in Premenopausal Breast Cancer Patients Receiving Adjuvant Hormonal Therapy (ABCSG-012) Premenopausal patients Stages I and II ER+ and/or PR+ Planned enrollment = 1,250 (3 BMD measurements available for 172 patients) Surgery (+XRT) Goserelin 3.6 mg/28days R A N D O M I Z E Tamoxifen + Zoledronic acid (4 mg)* q 6 mo Tamoxifen + placebo Anastrozole + Zoledronic acid (4 mg)* q 6 mo Anastrozole + placebo Baseline BMD 6-month BMD 3 years Final BMD *8 mg reduced to 4 mg. Gnant M, et al. San Antonio Breast Cancer Symposium Abstract 12.
15 Lumbar Spine BMD (g/cm 2 ) Zoledronic Acid Protects Against Anastrozole-Induced Bone Loss Preliminary Analysis p< Tamoxifen + Zoledronic Acid p=0.43 Anastrozole + Zoledronic Acid Tamoxifen Anastrozole 172 of 667 women had 3 BMDs, mean age 44.8 years Gnant M, et al. San Antonio Breast Cancer Symposium Abstract 12.
16 Clinical Guidelines Diamond et al. Cancer 2004;100: Clinical presentation Investigation Management Any fracture (minimal trauma) Spine X-rays Fracture on T/LS spine x-ray T- Score Suspected vertebral FX BMD < -2.5 (osteoporosis) Bisphosphonate Therapy Risk for FX ADT Previous FX DEXA or QCT -1 to -2.5 (osteopenia) >-1 (normal) Repeat BMD after 6-12 mos Repeat BMD after 2 yrs Modified from Diamond et al. cancer 2004;100:
17 The Challenges of Management of Breast Cancer-related Bone Loss Current 59 yr-old female first evaluated at age 32 yrs for pregnancy-related osteoporosis Vertebral fractures at T9 and T12 Only potential cause was thyroiditis leading to subsequent hypothyroidism Treated with calcium/vitamin D, subcutaneous calcitonin; started on alendronate in (42y) developed ER+/PR+ left breast cancer Surgery, FAC Chemotherapy, Radiation Chemotherapy-induced cessation of periods for 9 month before restarting Tamoxifen 2001 at age 44 y develop permanent menopause Tamoxifen
18 BMD (gm/cm2) Management of a 59 Year Old with Breast Cancer and Past History of Pregnancy-related Osteoporotic Fractures 0.85 Pregnancy-related fractures in mid-1980s Left breast cancer with lymph node metastasis & Surgery FAC Chemotherapy induced menopause Radiotherapy Menopause Tamoxifen Letrozole Raloxifene Rising CA Feb, 2010-present 0.5 exemustane 0.9 Lumbar Spine Total Hip Femoral Neck 7-8% Decline at hip sites with initiation of aromatase inhibitor Date
19 The Challenges of Management of Breast Cancer-related Bone Loss Letrozole Discontinued because of side-effects Continued alendronate Would you do anything more?
20 BMD (gm/cm2) Management of a 59 Year Old with Breast Cancer and Past History of Pregnancy-related Osteoporotic Fractures 0.85 Pregnancy-related fractures in mid-1980s Left breast cancer with lymph node metastasis & Surgery FAC Chemotherapy induced menopause Radiotherapy Menopause Tamoxifen Letrozole Raloxifene Rising CA Feb, 2010-present 0.5 exemustane 0.9 Lumbar Spine Total Hip Femoral Neck Date
21 BMD (gm/cm2) Management of a 59 Year Old with Breast Cancer and Past History of Pregnancy-related Osteoporotic Fractures 0.85 Pregnancy-related fractures in mid-1980s Left breast cancer with lymph node metastasis & Surgery FAC Chemotherapy induced menopause Radiotherapy Menopause Tamoxifen Letrozole Raloxifene Rising CA Feb, 2010-present 0.5 exemustane 0.9 Lumbar Spine Total Hip Femoral Neck Date
22 Rising CA 27.29
23 The Challenges of Management of Breast Cancer-related Bone Loss Presumed recurrence of breast cancer, although no metastatic disease identified Raloxifene discontinued Feb 2010 started exemustane What would you do?
24 Rising CA 27.29
25 Bone Turnover Markers 1000 Serum Osteocalcin (ng/ml) Serum CTX (pg/ml) Serum Osteocalcin and CTX /6/99 4/19/01 9/1/02 1/14/04 5/28/05 10/10/06 2/22/08 7/6/09 11/18/10 4/1/12
26 BMD (gm/cm2) Management of a 59 Year Old with Breast Cancer and Past History of Pregnancy-related Osteoporotic Fractures 0.85 Pregnancy-related fractures in mid-1980s Left breast cancer with lymph node metastasis & Surgery FAC Chemotherapy induced menopause Radiotherapy Menopause Tamoxifen Letrozole Raloxifene Rising CA Feb, 2010-present 0.5 exemustane 0.9 Lumbar Spine Total Hip Femoral Neck Date
27 What Would You Do?
28 What We Did Discontinued alendronate Initiated denosumab 60 mg every 6 months
29 Bone Turnover Markers 1000 Serum Osteocalcin (ng/ml) Serum CTX (pg/ml) Serum Osteocalcin and CTX /6/99 4/19/01 9/1/02 1/14/04 5/28/05 10/10/06 2/22/08 7/6/09 11/18/10 4/1/12
30 BMD (gm/cm2) Management of a 59 Year Old with Breast Cancer and Past History of Pregnancy-related Osteoporotic Fractures 0.85 Pregnancy-related fractures in mid-1980s Left breast cancer with lymph node metastasis & Surgery FAC Chemotherapy induced menopause Radiotherapy Menopause Tamoxifen Letrozole Raloxifene Rising CA Feb, 2010-present 0.5 exemustane 0.9 Lumbar Spine Total Hip 7-8% Decline at hip sites with initiation of aromatase inhibitor Femoral Neck Date
31 Current T-Scores Lumbar Spine -1.7 Total Hip -1.6 Femoral Neck -1.8
32 Is This Patient a Candidate for Treatment with Teriparatide? Current bone density not in osteoporotic range and no recent history of fracture Prior history of radiation therapy Even if she had not been treated with XRT, concern about treatment with teriparatide in patient with breast cancer that is active or undetermined
33 What would you do if she developed a vertebral fracture without history of trauma?
34 Prostate Cancer and Bone Loss
35 Causes of Bone Loss in Prostate Cancer patients Bilateral Orchiectomy Androgen Deprivation RX Chemotherapy Steroids Hypogonadism XRT Bone Loss Pfeilschifter J and Diel IJ. J Clin Oncol 2000;18:
36 Androgen Deprivation Therapy Decreases Bone Mineral Density Change from Study N Treatment Baseline BMD at 12 months Eriksson et al 1 11 Orchiectomy Hip: -9.6% Radius: -4.5% Maillefert et al 2 12 GnRH agonist Hip: -3.9% L spine: -4.6% Daniell et al 3 26 Orchiectomy or Hip: -2.4% GnRH agonist Berrutti et al 4 35 GnRH agonist Hip: -0.6% L spine: -2.3% Higano 5 16 LHRH agonist plus AA Hip: -2.5% L spine: -4.5% 1. Eriksson S, et al. Calcif Tissue Int. 1995;57: Maillefert JF, et al. J Urol. 1999;161: Daniell HW, et al. J Urol. 2000;163: Berruti A, et al. J Urol. 2002;167: Higano, Proc Am Soc Clin Oncol 1999;18:314a.
37 Androgen Deprivation Therapy (GNRH) Decreases Bone Mineral Density 12-month analysis P <.001 Lumbar spine Total hip Mittan D, et al. J Clin Endocrinol Metab. 2002;87:
38 Bone Turnover Increases During Androgen Deprivation Therapy Urine N-telopeptide (NTX) P<0.05 P<0.05 Bone ALP 6 months 12 months 6 months 12 months Control Gonadotropin-releasing hormone agonist (GnRHa) Adapted with permission from Mittan D et al. J Clin Endocrinol Metab. 2002;87:
39 Bone Density Decreases Rapidly After Orchiectomy * 1 year observations *P<0.05. Eriksson S et al. Calcif Tissue Int. 1995;57:97-99.
40 Androgen Deprivation Therapy 50 Increases Fracture Risk Cumulative incidence (%) Postorchiectomy No orchiectomy Years Adapted with permission from Daniell HW. J Urol. 1997;157:
41 What should be done?
42 Pamidronate to Prevent ADT-induced Bone Loss in 47 Prostate Cancer Pts Recurrent or locally advanced CaP; negative bone scan (N = 47) Randomize ADT + pamidronate (60 mg q 3 months) ADT Primary endpoint = bone mineral density Smith MR, et al. N Engl J Med. 2001;345: ADT = Androgen Deprivation Therapy
43 Mean percent change from baseline 12-month data Pamidronate Prevents ADT-induced Bone Loss P<0.005 for each comparison -1-2 No pamidronate Pamidronate Lumbar spine Total hip Smith MR, et al. N Engl J Med. 2001;345:
44 Thank You! Questions?
Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationAgenda. Adjuvant Bisphosphonates: Ready For Prime Time? The Osteoporosis Equation. Risk Factors for Osteoporosis. Charles L.
Adjuvant Bisphosphonates: eady For Prime Time? The Osteoporosis Equation Aging, family history, race, menopause [estrogen deficiency] diet, exercise, smoking, alcohol, meds Charles L. Shapiro, MD Director
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationBreast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield
Breast Cancer and Bone Health Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield Breast Cancer and Bone Health Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationOsteoporosis management in cancer patients
Osteoporosis management in cancer patients Belgian Menopause Society - Osteoporosis - Brussels, Oct 2017 Prof. JJ Body CHU Brugmann Univ. Libre de Bruxelles Brussels Bone loss associated with hormone ablation
More information4.7 Studies of Quality Holy Cross Hospital Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017
4.7 Studies of Quality Holy Cross Hospital 2017 Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017 Bone Health in Stage I ER/PR Positive Breast Cancer Patients To review
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationCancer Treatment Induced Bone Loss Fisiopatologia. Airoldi Mario S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino
Cancer Treatment Induced Bone Loss Fisiopatologia Airoldi Mario S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino Il nuovo concetto di bone health nel paziente neoplastico OSTEOPOROSI
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationFrancesco Bertoldo. Metabolic Bone Diseases and Osteoncology Unit DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY
DRUG INDUCED S OSTEOPOROSIS: ANDROGEN DEPRIVATION THERAPY Francesco Bertoldo Metabolic Bone Diseases and Osteoncology Unit Department of Medicine University di Verona EPIDEMIOLGY OF PROSTATE CANCER Prostate
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationMedical Review. The following slides were medically reviewed by Dr. Nancy Dawson in June 2018.
Bone Health Medical Review The following slides were medically reviewed by Dr. Nancy Dawson in June 2018. Presentation Overview 1. What is bone health? 2. How can cancer and cancer treatments affect your
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationMedication Associated Osteoporosis
Medication Associated Osteoporosis Drugs that are bad for the bones Jonathan Graf, MD Associate Professor of Clinical Medicine UCSF Director UCSF Rheumatoid Arthritis Clinic Necessary Therapies Preventable
More informationOsteoporosis in Men Professor Peter R Ebeling
Osteoporosis in Men MD FRACP Head, Department of Medicine, School for Clinical Sciences Monash Health Translation Precinct Monash University, Clayton, Victoria 1 MonashHealth Potential Conflicts Departmental
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationAndrogen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Celestia S Higano SUMMARY Androgen deprivation therapy (ADT) alone or in combination with
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationIssues in Cancer Survivorship. Larissa A. Korde, MD, MPH June 26, 2010
Issues in Cancer Survivorship Larissa A. Korde, MD, MPH June 26, 2010 Estimated US Cancer Cases in Women: 2006-2008 CA Cancer J Clin 2006; 56:106-130; CA Cancer J Clin 2008;58:71 96. Relative Survival*
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationClinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
Hindawi Publishing Corporation Prostate Cancer Volume 2, Article ID 7664, 7 pages doi:.55/2/7664 Clinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationBone health a key factor in elderly and not so elderly patients with cancer
Bone health a key factor in elderly and not so elderly patients with cancer Matti S. Aapro IMO Genolier Switzerland COI Dr Aapro is a consultant for Amgen, BMS, Celgene, Eisai, Genomic Health, GSK, Helsinn,
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationToremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Matthew R. Smith,*,, Ronald A. Morton,* K. Gary Barnette,* Paul R. Sieber, S. Bruce Malkowicz, Domingo
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationNew Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence
New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More informationA Review of Bone Health Issues in Oncology
A Review of Bone Health Issues in Oncology David L. Kendler MD FRCPC CCD Professor of Medicine (Endocrinology) University of British Columbia Vancouver Canada Disclosures David Kendler has received research
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationBAD for the Bones Skeletal Woes from Commonly Prescribed Medications
BAD for the Bones Skeletal Woes from Commonly Prescribed Medications A Case of Skeletal Cruelty Phenobarbitol Arimidex Heparin Jonathan Graf, MD Asst. Professor Medicine, UCSF Div. Rheumatology, SFGH Prednisone
More informationLa salute dell osso nelle pazienti in trattamento adiuvante. Airoldi Mario - S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino
La salute dell osso nelle pazienti in trattamento adiuvante Airoldi Mario - S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino BONE STRENGTH OSTEOPOROSIS SKELETAL DISORDER COMPROMISING
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationHormone therapy in Breast Cancer patients with comorbidities
Hormone therapy in Breast Cancer patients with comorbidities Diana Crivellari Centro di Riferimento Oncologico Aviano- ITALY Madrid November 9th, 2007 Main issues Comorbidities in elderly women Hormonal
More informationHanan Shawky 1 and Tarek Gamil 2.
Relationship of Combined Androgen Deprivation Therapy and Bone Turnover Markers with Bone Mineral Density, Lean Body Mass and Fat Content in Patients with Non- Metastatic Prostate Cancer Hanan Shawky 1
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationSurviving Breast Cancer
Surviving Breast Cancer What to expect after completing treatment Dexter T. Estrada, MD Hematology Oncology Medical Group of Fresno, Inc. November 3, 2012 Epidemiology & Survival Estimates Breast cancer
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationAdjuvant bisphosphonates: our recommendations
Adjuvant bisphosphonates: our recommendations Andreas Makris Mount Vernon Cancer Centre OPTIMA launch meeting, 27 April 2017 Breast Cancer Metastasis Tumour cell colonisation of bone Tumour cell proliferation
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More information[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationMedication Policy Manual. Topic: Prolia, denosumab Date of Origin: August 11, 2010
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru223 Topic: Prolia, denosumab Date of Origin: August 11, 2010 Committee Approval Date: August 11,
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationOSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE. Lydia Au Geriatrics Ng Teng Fong Hospital
OSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE Lydia Au Geriatrics Ng Teng Fong Hospital LET S START WITH WHAT YOU WANT TO KNOW AND DO WITH A VERT FRACTURE Vertebral fractures Most common (550K
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other PROLIA, XGEVA 37012 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request for prior authorization. All requests
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationHormones Impact on Bone Health Throughout the Lifespan. Outline. Sex differences in: Osteoporosis and fracture rates. Secondary causes of osteoporosis
Hormones Impact on Bone Health Throughout the Lifespan Meryl S. LeBoff, MD Director, Skeletal Health and Osteoporosis Chief, Calcium and Bone Section Brigham and Women s Hospital Professor of Medicine,
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationTEAM SCIENCE AT A PROGRAMMATIC LEVEL. Sundeep Khosla, M.D. Mayo Clinic College of Medicine
TEAM SCIENCE AT A PROGRAMMATIC LEVEL Sundeep Khosla, M.D. Mayo Clinic College of Medicine APPROACH TO TRANSLATIONAL RESEARCH IN OSTEOPOROSIS Epidemiological Studies Clinical Investigation Mouse and Cellular
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationUpdate from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002
Update from the 25th Annual San Antonio Breast Cancer Symposium December 11 14, 2002 Nearly 5,000 physicians, oncologists, radiologists, epidemiologists, basic scientists, and breast cancer advocates from
More informationNew Developments in Oncology Bone Health. Learning Objectives. Disclosures 10/1/2014
New Developments in Oncology Bone Health Kamakshi V. Rao, Pharm.D., BCPOP, CPP, FASHP Clinical Manager, Pharmacy Residency Programs Oncology and Bone Marrow Transplant Clinical Pharmacist University of
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More information